Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$2.51 USD
+0.01 (0.40%)
Updated Dec 26, 2024 11:44 AM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGMO 2.51 +0.01(0.40%)
Will SGMO be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
Beyond Air, Inc. (XAIR) Reports Q2 Loss, Lags Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
Other News for SGMO
Sangamo Biosciences: Strategic Neurology Advancements and Financial Growth Potential with Astellas Partnership
Biggest stock movers Thursday: ACN, MU, MESO, and more
Sangamo spikes on Astellas licensing deal for gene therapy tech
US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket